- 全部删除
您的购物车当前为空
Clivatuzumab为人源化抗粘液素单抗,可靶向大部分胰腺癌细胞表面高表达的MUC1表位,对多种肿瘤细胞均有较好的治疗效果。
Clivatuzumab为人源化抗粘液素单抗,可靶向大部分胰腺癌细胞表面高表达的MUC1表位,对多种肿瘤细胞均有较好的治疗效果。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 1,990 | In stock | |
| 5 mg | ¥ 4,790 | In stock | |
| 10 mg | ¥ 6,680 | In stock | |
| 25 mg | ¥ 9,920 | In stock |
Clivatuzumab 相关产品
| 产品描述 | Clivatuzumab is a humanized anti-myxinomab, which can target the MUC1 epitope highly expressed on the surface of most pancreatic cancer cells, and has a good therapeutic effect on a variety of tumor cells. |
| 体外活性 | Clivatuzumab 对胰腺导管腺癌(PDAC)表现出高度特异性,对正常及良性的非肿瘤胰腺组织几乎不表现出反应。尽管它对其他某些器官(如胃、结肠和肺)的腺癌反应有限(大约10%的样本)[1]。 |
| 别名 | 克利妥珠单抗 |
| 分子量 | 145.42 kDa |
| CAS No. | 1622075-09-5 |
| 颜色 | Transparent |
| 物理性状 | Liquid |
| 存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容